Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  Biochemical Engineering >  Inhibitors >  VcMMAE

VcMMAE

Basic information Safety Supplier Related

VcMMAE Basic information

Product Name:
VcMMAE
Synonyms:
  • VcMMAE
  • MC-Val-Cit-PAB-MMAE
  • Maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl-monomethyl auristatin E
  • 4-((S)-2-((S)-2-(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamido)-3-methylbutanamido)-5-ureidopentanamido)benzyl((S)-1-(((S)-1-(((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-y
  • MC-VC-PAB-MMAE
  • MC-VC-PAB-MMAE,MC-Val-Cit-PAB-MMAE
  • maleimido-caproyl-val-Cit-PAB-MMAE
  • VeMMAE
CAS:
646502-53-6
MF:
C68H105N11O15
MW:
1316.63
Product Categories:
  • ADCs
  • ADC
  • ADC LINKER
  • 646502-53-6
Mol File:
646502-53-6.mol
More
Less

VcMMAE Chemical Properties

Boiling point:
1347.6±65.0 °C(Predicted)
Density 
1.196±0.06 g/cm3(Predicted)
storage temp. 
Sealed in dry,Room Temperature
solubility 
Soluble in DMSO, DCM, DMF
form 
A solid
pka
13.29±0.70(Predicted)
color 
White to off-white
InChI
InChI=1/C68H105N11O15/c1-15-43(8)59(51(92-13)38-55(83)78-37-23-27-50(78)61(93-14)44(9)62(85)71-45(10)60(84)47-24-18-16-19-25-47)76(11)66(89)57(41(4)5)75-65(88)58(42(6)7)77(12)68(91)94-39-46-29-31-48(32-30-46)72-63(86)49(26-22-35-70-67(69)90)73-64(87)56(40(2)3)74-52(80)28-20-17-21-36-79-53(81)33-34-54(79)82/h16,18-19,24-25,29-34,40-45,49-51,56-61,84H,15,17,20-23,26-28,35-39H2,1-14H3,(H,71,85)(H,72,86)(H,73,87)(H,74,80)(H,75,88)(H3,69,70,90)/t43-,44+,45+,49-,50-,51+,56-,57-,58-,59-,60+,61+/s3
InChIKey
NLMBVBUNULOTNS-NNNQBTKHNA-N
SMILES
[C@@H](C(=O)N[C@H](C(=O)N(C)[C@@H]([C@@H](C)CC)[C@@H](CC(N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C1C=CC=CC=1)=O)OC)C(C)C)(C(C)C)N(C)C(=O)OCC1C=CC(NC(=O)[C@@H](NC(=O)[C@H](C(C)C)NC(CCCCCN2C(=O)C=CC2=O)=O)CCCNC(=O)N)=CC=1 |&1:0,4,9,10,14,21,22,25,30,32,62,66,r|
More
Less

VcMMAE Usage And Synthesis

Description

MC-Val-Cit-PAB-MMAE is a precursor of antibody drug conjugate. It contains a thio reactive maleimidocaproyl (MC) group, a protease-sensitive Val-Cit dipeptide, a PABC linker and a MMAE payload. The MMAE is a synthetic antineoplastic agent. It can be attached to a monoclonal antibody (MAB) which directs it toward cancer cells.

Uses

Vedotin is an ultra-high-affinity small organic ligand of fibroblast activation protein used for tumor-targeting applications

Application

VcMMAE is a MMAE derivative with valine-citrulline (Vc) linker. VcMMAE can be used to make antibody drug conjugate. VcMMAE is a anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc). Monomethyl auristatin E (MMAE) is a synthetic antineoplastic agent. Because of its toxicity, it cannot be used as a drug itself; instead, it is linked to a monoclonal antibody (MAB) which directs it to the cancer cells. In International Nonproprietary Names for MMAE-MAB-conjugates, the name vedotin refers to MMAE plus its linking structure to the antibody. It is a potent antimitotic drug derived from peptides occurring in marine shell-less mollusc Dolabella auricularia called dolastatins which show potent activity in preclinical studies, both in vitro and in vivo, against a range of lymphomas, leukemia and solid tumors. These drugs show potency of up to 200 times that of vinblastine, another antimitotic drug used for Hodgkin lymphoma as well as other types of cancer?

Biological Activity

VcMMAE is an antibody-drug conjugate (ADC) with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc). As a monoclonal antibody, it acts by binding to the extracellular domain of epidermal growth factor receptor (EGFR) and blocking its interaction with the ligands, thereby inhibiting cellular proliferation.

in vitro

MMAE is efficiently released from SGN-35 within CD30 cancer cells and, due to its membrane permeability, is able to exert cytotoxic activity on bystander cells+. MMAE sensitized colorectal and pancreatic cancer cells to IR in a schedule and dose dependent manner correlating with mitotic arrest. Radiosensitization is evidenced by decreased clonogenic survival and increased DNA double strand breaks in irradiated cells.

in vivo

MMAE in combination with IR results in tumor growth delay, tumor-targeted ACPP-cRGD-MMAE with IR produces a more robust and significantly prolonged tumor regression in xenograft models.

target

Auristatin

VcMMAESupplier

Levena (Suzhou) Biopharma Co., Ltd. Gold
Tel
0512-81877925 051281877925
Email
info@levena.cn
Shanghai ruichang pharmaceutical technology co., LTD Gold
Tel
18621054990
Email
maychemicals@sina.com
Shanghai Haoyuan Chemexpress Co., Ltd. Gold
Tel
021-58950125
Email
info@chemexpress.com
Shanghai Send Pharmaceutical Technology Co., Ltd. Gold
Tel
+86-021-50266790 Q2816483246
Email
sale@shsendpharm.com
Jinan Chengquan Chemical Co., Ltd Gold
Tel
13616405505 13616405505
Email
zhulinsun1@126.com